Aerie's Roclanda on par with Allergan's Ganfort in glaucoma study

Aerie Pharmaceuticals (NASDAQ:AERI) announces positive preliminary data from its six-month Phase 3b trial in Europe, Mercury 3, comparing Roclanda (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% to Allergan's (NYSE:ABBV) Ganfort (bimatoprost 0.3 mg/mL and timolol maleate equivalent to timolol 5 mg/mL) for reducing intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Topline data are anticipated in early 2021.

Roclanda demonstrated overall non-inferiority to Ganfort over 90 days, with consistent IOP reduction throughout the day of ~9.5 millimeters of mercury (mmHg) for an average reduction from baseline IOPs of ~37%. IOP reductions and incidence of ocular adverse events were better than two previous Phase 3 studies.

The company expects European approval early next year.

Roclanda is marketed in the U.S. as Rocklatan (netarsudil and latanoprost ophthalmic solution). Ganfort is approved in Europe but not in the U.S.

https://seekingalpha.com/news/3616935-aeries-roclanda-on-par-allergans-ganfort-in-glaucoma-study